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Environmental teratogenic factors (e.g. alcohol) are preventable. We focus our analysis on human teratogenic drugs 
which are not used frequently during pregnancy. The previous human teratogenic studies had serious methodological 
problems, e.g. the first trimester concept is outdated because environmental teratogens cannot induce congenital 
abnormalities in the first month of gestation. In addition, teratogens usually cause specific congenital abnormalities or 
syndromes. Finally, the importance of chemical structures, administrative routes and reasons for treatment at the 
evaluation of medicinal products was not considered. On the other hand, in the so-called case-control epidemiological 
studies in general recall bias was not limited. These biases explain that the teratogenic risk of drugs is exaggerated, 
while the benefit of medicine use during pregnancy is underestimated. Thus, a better balance is needed between the risk 
and benefit of drug treatments during pregnancy. Of course, we have to do our best to reduce the risk of teratogenic 
drugs as much as possible, however, it is worth stressing the preventive effect of drugs for maternal diseases (e.g. 
diabetes mellitus and hyperthermia) related congenital abnormalities.  
Key words: human teratogenic drugs, congenital abnormalities, critical period, recall bias, congenital abnormality, preventive effect 
of drugs. 
1.  Introduction  
Among environmental factors, dangerous lifestyle 
seems to be the greatest hazard for the development of the 
fetus due to the common practice of consuming alcohol 
and smoking tobacco. Alcohol may cause fetal alcohol 
syndrome or at least fetal alcohol effects [1,2]. It is 
preventable by abstinence during pregnancy but often 
unavoidable because approximately 50% of pregnancies 
are unplanned and hence alcohol consumption occurs 
before a woman knows that she is pregnant. Recently the 
teratogenic potential of smoking has been shown in some 
congenital abnormalities (CAs), particularly terminal 
transverse type of limb deficiencies [3] and Poland 
sequence [4], while the gene-environmental interaction 
was shown in the origin of orofacial clefts [5]. The role of 
teratogenic effect of environmental pollutants such as 
methyl mercury [6] was also reported but we cannot 
estimate the magnitude of this problem. The primary 
prevention of infectious diseases by vaccination is 
extremely important particularly in the prevention of CA-
syndromes caused by rubella and varicella viruses. Here 
we focus on teratogenic medication and their prevention. 
2.  Human teratogenic drugs 
In Hungary 92% of pregnant women used medicinal 
products and the mean number of drugs and pregnancy 
supplements per pregnant women was 3.4 between 1980 
and 1996. About 70% pregnant women were treated with 
drugs during pregnancy [7]. These figures are in 
agreement with a recent publication [8]. 
Experts in many countries have set up risk 
classification systems based on data from human and 
animal studies to help physicians interpret the risk 
associated with drugs during pregnancy. The most well-
known classification was introduced by the US Food and 
Drug Administration (FDA) in 1979, using the letters A, B, 
C, D and X for five categories [9]. The definition of 
category A means no risk, and any risk is unlikely in 
category B. There is no appropriate data for drugs in 
category C. The definition of category D is as follows: 
“There is positive evidence of human fetal risk, but the 
benefits from use in pregnant women may be acceptable 
despite the risk” (e.g. in a life-threatening situation). 
Finally, drugs with classification X are “Contraindicated 
in women who are or may be pregnant”. We do not like 
this classification system, because all oral contraceptives 
and female sex hormones (both estrogens and progestins) 
w e r e  c l a s s i f i e d  a s  X  t h o u g h  w e  h a v e  n o  e v i d e n c e  o f  a  
teratogenic effect. It is another matter that these hormones 
are not indicated during pregnancy. We only found an 
association between very high doses of oestrogens and 
unimelic terminal transverse type of limb deficiency when 
oestrogens were used to induce illegal abortion [10]. This 
general teratogenic risk for limb deficiency was about 1% 
instead of the usual 0.05%. On the other hand teratogenic 
and fetotoxic effects are confused though they have 
different time factors and consequences. Finally some 
other drugs were classified as X without any evidence for 
teratogenic risk (e.g. clomiphene) or with much debated 
findings (e.g. benzodiazepine such as flurazepam, 
quazepam, temazepam and triazolam). This problem is 
more serious in the groups of drugs with classification D 
because many drugs were classified without any data and 
were based only on the general similarity of the chemical 
structure. However, mild differences in the chemical 
structure can change the teratogenic potential, for 
example the teratogenic oxytetracyclines and non-
teratogenic doxycycyline within the group of 
tetracyclines. At present the population-based Hungarian 
Case-Control Surveillance of Congenital Abnormalities 
(HCCSCA) [11] contains the largest national case-control 
data set in the world where the teratogenicity of about a Int. J. Med. Sci. 2005 2  101
hundred drugs was studied. Our findings do not confirm 
the teratogenic risk of benzodiazepines such as diazepam  
[12], chlordiazepoxide [13], nitrazepam, medazepam, 
tofisopam, aplrazolum and clonazepam [14]. The 
teratogenic effect of diazepam and some other 
benzodiazepines was not confirmed after self-poisoning 
(i.e. suicide attempt) with extremely large doses [15,16]. 
The teratogenic effect of barbitals [17], furosemide [18], 
aminoglycoside antibiotics  [19] and povidone-iodine [20] 
was also not found. After the negative findings of our 
studies we cannot accept the risk estimation of the FDA 
classification system. Similar opinions were stated by 
other experts as well, therefore two other drug 
classification systems have been developed in Sweden [21] 
and Australia  [22]. 
There are about 8,200 medicinal products in the 
Hungarian market, however, the number of chemical 
substances, i.e. generic drugs with human teratogenic risk 
is limited. Table 1 shows drugs with high and moderate 
teratogenic risk. Thalidomide was never marketed in 
Hungary, however, it is used again in some countries 
(e.g., Brazil) as an effective drug for leprosy and other 
diseases. Androgenic hormones are not indicated in the 
treatment of pregnant women, nevertheless some women 
used these drugs at the beginning of their unplanned 
pregnancies due to their body building activity. At 
present isotretinoin and etretinate are considered the most 
teratogenic risk used for the treatment of acne and 
psoriasis in Hungary, therefore an effective campaign was 
organized to prevent their use during pregnancy. The 
coumarin derivatives cause the largest clinical problem 
because pregnant women with a previous thrombosis 
history frequently need treatment. However, it is possible 
to change the treatment protocol and use heparin instead 
of coumarin derivatives in the early pregnancy because 
the latter drugs are teratogenic in the third and fourth 
months of gestation. Oxytetracyclines are also teratogenic, 
but these products are now not on the market. The use of 
oxytetracyclines was relatively frequent in Hungarian 
pregnant women, thus we were able to show that Tetran® 
induced – other than staining of deciduous teeth – a 
characteristic pattern of multiple CA [23].On the other 
hand doxycycline is not teratogenic [24]. The use of D-
penicillamine (e.g. in Wilson disease) rarely occurs and it 
may cause cutis laxa, not a severe CA. In addition this CA 
can be diminished by the parallel use of zinc. 
Diethylstilbestrol was also withdrawn from the market. 
The proportion of women treated with drugs with high 
and moderate teratogenic risk during the study pregnancy 
was 0.8% and 0.4% in the group of cases with CAs and 
controls without CAs in the data set of the HCCSCA, 
1980-2002, respectively. 
The list of drugs with low and very low teratogenic risk 
is longer (Table 2), though the names of drugs with 
fetotoxic effects, e.g., chlorothiazide, angiotensin-
converting enzyme inhibitors, beta-adrenergic blocking 
agents, reversible goiter inducing potassium iodine, etc, 
are not mentioned. There is a long list of antineoplastic 
and anticonvulsant drugs which may be needed in 
pregnant women with cancer or epilepsy. At present some 
of them are not on the market, but most drugs in this list 
have a teratogenic risk between 2 and 5%. Ergotamine and 
quinine derivatives were used relatively frequent. Among 
oestrogens and retinol (vitamin A), only high dose 
treatments are considered. It is worth mentioning that we 
had three mothers who were treated by 50,000 and one 
with 100,000 IU doses of vitamin A daily in the first and 
second months of gestation, and later they delivered 
newborn infants without any CAs [25]. Our finding is in 
agreement with the conclusion of the European Network 
of the Teratology Information Services, whose data set did 
not provide evidence for an increased risk of major CAs 
associated with high vitamin A intake (10,000 IU per day 
or more) during the organogenetic period of embryo [26].  
Here we discuss three problems at the evaluation of 
human teratogenic risk of drugs. 
I. Low scientific quality of previous human teratogenic 
studies 
Unfortunately the scientific quality of most previous 
studies regarding risk estimation of teratogenic 
medications was low due to some methodological 
problems. 
Time factor: first trimester concept is outdated 
The first trimester of pregnancy was considered as 
the critical period of most major CAs. This supposition is 
unscientific and outdated [27]. 
At present gestation age is calculated from the first 
day of the last menstrual period. Thus, “pregnant 
women” are not pregnant in the first two weeks of their 
pregnancies. The third week covers the preimplantation 
period when the zygote goes from the external end of the 
Fallopian tube to the uterus. The fourth week comprises 
the implantation period when the blastocyst finds its site 
in the uterus. However, the zygotes and blastocysts have 
continuous mitoses producing totipotent stem cells during 
this period. Serious damage can cause their death, but 
after limited damage they have a complete recovery. 
These facts explain the rule of “all-or-nothing effect” or in 
other words the consequence of these damages have only 
two outcomes: complete loss of zygotes/blastocysts 
(which causes only some delay in the seemingly 
menstrual bleeding) or healthy birth. 
In conclusion, human teratogenic drugs cannot 
induce CA in the first month of gestation because the 
specific activation of DNA in the stem cells and the so-
called differentiation of specific cells, organs and body 
forms starts on the 29th day of gestation (or on the 15th 
postconception day). The 29th day of gestation overlaps 
with the first days of missing menstrual bleeding when 
women in general can recognize the pregnancy. Thus, it is 
necessary to know that before the first missed menstrual 
bleeding, environmental factors cannot induce CAs. The 
main organ-forming period lasts from the 29th day to the 
70th day of gestation. The evaluation of the first trimester 
is therefore a serious methodological error, only the second 
and third months represent the critical period of most major 
CAs. On the other hand we know that the critical period of 
some CAs exceeds the end of third month, e.g., the critical 
period of posterior cleft palate and hypospadias covers 
the 12th-14th and 14th-16th weeks of gestation, while the 
critical period of undescended testis and patent ductus 
arteriosus is 7 to 9 months and 9 to 10 months, 
respectively. Thus, the optimal approach is to consider the 
specific critical period of each CA [7] separately. 
Specificity of teratogens 
It is not worth studying the total group of CAs 
because CAs have different etiological backgrounds. 
Therefore we have to focus our analysis on specific CAs 
since teratogenic drugs induce specific CAs without 
affecting other CAs and overall rates. Thus, we have to do Int. J. Med. Sci. 2005 2  102
our best to develop groups of CAs as homogeneous as 
possible. In addition the most teratogenic drugs cause 
specific CA syndromes with a characteristic pattern of 
component CAs. This phenomenon explains the 
delineation of fetal alcohol, radiation, rubella, hydantoin-
phenytoin, warfarin-coumarin, accutane, etc. syndromes. 
This rule helps us to identify the cause of specific CA-
syndrome, e.g., if a case is affected with cleft lip and nail 
hypoplasia, we can diagnose hydantoin (phenytoin) CA-
syndrome in a baby of an epileptic mother who has been 
treated with this drug. 
Another common and serious methodological error 
occurs when isolated (single) and multiple (syndromic) 
manifestations of the seemingly same CAs are combined 
and evaluated together. Most isolated CAs have a 
complex etiology based on some polygenic predisposition 
which is triggered by environmental risk factors. The 
seemingly similar component CAs within 
multimalformed or syndromic cases are caused by 
chromosomal aberrations, gene mutations or teratogens 
[28]. We can easily prove the different etiopathogenetic 
background of isolated and multiple CAs by 
epidemiological methods. For example, isolated cleft lip 
has a left sided and male predominance while component 
cleft lip in syndromic cases has no side predominance and 
the sex ratio corresponds to the usual population figure 
[29]. Thus, it is an important rule to evaluate the isolated 
and multiple manifestations of the same CA separately. 
The importance of different chemical structures, administrative 
routes and reasons for treatment at the teratogenic evaluation of 
medicinal products was not considered 
In general, similar drugs were evaluated together 
such as penicillins, tetracyclines, cephalosporins (or 
sometimes as “antibiotics”) and sulfonamides in the past. 
This approach is not correct because each drug within 
these groups has different chemical structure. As we 
mentioned previously within the group of tetracyclines, 
oxytetracylines [23] were teratogenic while doxycyclines 
[24] were not teratogenic. At the evaluation of seven orally 
used sulfonamides, only two showed teratogenic 
potential, and they induced different CAs [30]. 
Our studies showed the importance of interaction of 
different drugs. We were not able to find a clinically 
important teratogenic effect after the use of oral 
metronidazole [31] and the topical miconazole treatment 
resulted in an obvious negative finding [32]. Nevertheless, 
the vaginal use of the combination of these two drugs 
increased the risk for poly/syndactyly six fold [33]. 
Our analyses also demonstrated that it is necessary 
to differentiate the administrative route of drugs and their 
teratogenic potential. We should therefore evaluate the 
use of the same drugs (e.g., corticosteroids and antifungal 
agents) according to oral, parenteral, topical (skin, 
vaginal, eye and ear) and inhaled aerosol treatments 
separately. 
Finally it is necessary to differentiate drugs and 
pregnancy supplements within medicinal products. Drugs 
are used for the treatment of maternal diseases and 
pregnancy complications during pregnancy while 
pregnancy supplements such as folic acid, other vitamins 
[34], iron, calcium, multivitamins, etc are given to prevent 
pregnancy complications and unsuccessful pregnancy 
outcomes particularly CAs. These opposite effects of 
medicinal products have to be considered when 
evaluating the drugs. 
II. Recall bias 
The birth of an infant with a CA is a serious 
traumatic event for most mothers, who therefore try to 
find a causal explanation such as drug use during 
pregnancy, something that does not occur after the birth 
of a healthy infant. Thus the mothers of babies affected 
with CAs are continually thinking of possible dangerous 
environmental factors and when asked about the history 
of their pregnancy, give a long list of supposed agents. On 
the other hand the mothers of healthy babies are thinking 
of the present and future of their babies and are likely to 
forget events during the pregnancy. Retrospective (i.e., 
after the birth) maternal self-reported information 
therefore is different in the groups of case and control 
mothers and this recall bias can mimic an increased risk of 
drugs in the CA-groups up to an odds ratio of 1.9 (35). 
Thus a higher risk of less than 1.9 should be interpreted 
cautiously. In addition, it is possible to reduce recall bias. 
Firstly, we evaluate 25 CA-groups and we expect a 
higher occurrence of one or some CA-groups after the use 
of the given drug due to the specificity of teratogens. 
Recall bias may act for all CAs similarly. 
Secondly, the use of the drug under study is 
evaluated during the critical period of CA formation, in 
general the second and third months of gestation. We may 
suppose that the teratogenic effect of the drug is shown 
only during this period because we expect an 
underreporting of exposure in both the critical and non-
critical periods of CA formation in the mothers of healthy 
babies, i.e., in the population control group.       
Thirdly, an independent and prospective source of 
drug exposure data, e.g., the medically recorded data in 
the prenatal logbook may serve as a gold standard. Our 
validation study, however, showed that a small group of 
pregnant women (2.4%) did not use prescribed and 
medically recorded drugs or they shortened the duration 
of treatment due to the supposed teratogenic risk [36]. 
Another independent and prospective source of drug 
exposure can be found in pharmacy records [37]. 
Fourthly, it is worth using a patient control group 
including mothers of cases with other CAs. In our 
HCCSCA system, cases with Down syndrome are used as 
patient controls  [11] because the cause of this numerical 
chromosomal aberration (trisomy 21) is not connected 
with the teratogenic effect of agents during pregnancy, 
and particularly in the critical period of most CA 
formation, i.e., during the second and third months of 
gestation. 
Fifthly, “true” teratogens such as rubella virus, 
radiation, alcohol, hydantoin-phenytoin, warfarin-
coumarin, accutane, etc., cause multiple CA with a 
characteristic pattern of CAs. Thus multimalformed cases 
need a special and detailed analysis  [28] because these 
data are not distorted by recall bias. Another group of 
teratogens plays a role as trigger factors in the origin of 
isolated CAs based on polygenic-environmental 
interaction, i.e. multifactorial etiology. 
III. Teratogenic risk of drugs is exaggerated. 
The exaggeration of drug teratogenicity can be 
explained by several factors. 
1. At present the average number of children per 
family in Hungary is about 1.3 compared to 11 in the 19th 
c e n t u r y .  I n  t h e  p a s t ,  t h e  s o c i a l  r o l e  o f  f e m a l e s  w a s  t h e  
“reproduction” of human beings. Now they take part in 
the social “production” outside their homes similar to Int. J. Med. Sci. 2005 2  103
males but they have to fulfill their traditional role of 
reproduction as well. A malformed or disabled child 
curtails their social activity hence the emphasis on having 
a healthy baby. 
2. The positive findings of animal investigations are 
frequently extrapolated for the human fetus contrary to 
the well-known species specificity. 
3. The previous teratologic studies had several 
methodological weaknesses and recall bias which are 
summarized above and which resulted in false positive 
findings. 
4. The editors of scientific periodicals have an 
aversion to publishing papers with negative results, but 
are happy to publish selected case reports and the positive 
findings of animal and human epidemiological studies. 
This publication bias distorts the thinking of experts as 
well as the general population. 
5. The false balance of risk and benefit of drug use 
during pregnancy is seriously augmented by the 
defensive policy of pharmaceutical companies  and 
regulatory agencies which are gradually labeling most 
drugs with the recommendations to avoid their use 
during pregnancy, at least in “the first trimester”.  
6. This unbalanced opinion is amplified by a self 
defensive attitude of some doctors and is partly 
understandable. They may not be well informed and may 
exaggerate the risk by relying on manufacturers drug 
pamphlets. They may also be thinking about possible law 
suits and are therefore over cautious forgetting that the 
chance of any pregnancy ending with a baby who has a 
major CA is approximately 3%. 
The exaggeration of teratogenic risk of medicinal 
products causes several hazards. 
First, many pregnant women do not get the 
necessary drug treatment and it results in serious 
consequences both for the mothers and their fetuses. If 
influenza [38] and other acute infectious diseases of 
respiratory system [39] with high fever in early pregnancy 
are not treated by appropriate methods including drugs, 
therefore the teratogenic effect of hyperthermia can 
induce hyperthermic embryopathy (Table 3), among 
others, neural-tube defects. In Hungary, about 40 % of 
pregnant women have some sexually transmitted 
infections and/or diseases in their genital organs [40]. 
Most medical doctors do not dare to treat them, therefore 
the ascending infections are followed by preterm birth 
and serious intrauterine infection of the fetus. Our study 
showed that the fetuses of inappropriately or untreated 
asthmatic pregnant women have a higher risk for 
intrauterine growth retardation [41]. 
Second, many planned and wanted pregnancies are 
terminated due to the anxiety and fear created by the 
notion that nearly all drugs cause CAs [42]. Recently the 
number of induced abortions before the 12th week of 
gestation is about 60,000 per year in Hungary and about 
3,000 are terminated due to a medical indication 
connected to drug use during pregnancy. However, our 
analysis showed that the great majority of these 
pregnancy terminations had unfounded medical 
indications [43]. 
Third, pregnant women using necessary drug 
treatments may suffer permanent psychological stress and 
may be seriously depressed until the end of the pregnancy 
[44]. 
Fortunately the scientifically proved human 
teratogenic drugs are not used frequently in pregnant 
women (Table 1 and 2). The total proportion of CAs 
induced by drugs is less than 1 % in the database of the 
HCCSCA, if we calculate 65.27 per 1,000 total rate of CAs 
in Hungary [45]. 
3.  Benefit of medicine use during pregnancy is 
underestimated 
Maternal drug use during pregnancy may pose a 
teratogenic risk for the embryo. However, the 
recommendation to avoid all drugs during early 
pregnancy [42] is unrealistic and may be dangerous. 
About 8% of pregnant women need permanent drug 
treatment due to their chronic diseases such as epilepsy, 
diabetes mellitus, bronchial asthma, hypertension, thyroid 
disorders, migraine, and severe depression [40]. More 
pregnant women require transient drug treatment because 
of influenza, acute infectious diseases of respiratory 
system and urogenital organs, the latter mainly due to 
sexually transmitted infections. In addition, headache, 
nervousness, constipation and other common complaints 
may also need drug treatments. Finally there are many 
pregnancy complications such as nausea and vomiting, 
threatened abortion, preterm delivery, toxemia and 
anemia which may also require drug treatments. 
The benefits of medicine use during pregnancy are 
not restricted to the recovery of maternal health but also 
result in some advantages for the fetus as well, because 
the maternal well-being is important for the optimal 
development of the fetus. Poorly controlled diabetes 
mellitus, particularly type 1 is teratogenic. However, the 
appropriate management of diabetic pregnant women can 
prevent diabetic embryopathy [46]. In addition the 
effective treatment of infectious diseases of genital organs 
can significantly reduce the prevalence of preterm birth 
and its related effects, among others, undescended testis 
[47]. Finally the periconceptional folic acid or folic acid-
containing multivitamin supplementation can prevent 
most neural-tube defects [48] and a considerable number 
of CAs in the cardiovascular system, urinary tract and 
limb deficiencies [49-51]. 
Previously we mentioned that less than 1 % of CAs 
may be caused by human teratogenic drugs. The number 
of CAs induced by human teratogenic drugs is about 6 per 
1,000 on the basis of Table 1 and 2 (Table 3). Of course, we 
have to do our best to limit this risk. However, there is 
another aspect of CA prevention which is connected with 
drug use. High fever (at least 38.9°C) due to influenza [38] 
and acute respiratory diseases [39] during the second and 
third months of gestation occurs in about 4% of pregnant 
women in Hungary. Offspring of these pregnant women 
have a higher risk for neural-tube defects, cleft lip with or 
without cleft palate, posterior cleft palate and some other 
CAs. The total number of CAs which may be associated 
with hyperthermia is 8.7 per 1,000 and these CAs can be 
prevented by effective antifever therapy, including drugs 
(Table 3). Thus our estimation shows that CA-preventive 
effect of only antifever drugs may exceed the CA risk 
caused by all human teratogenic drugs. 
Thus, a better balance is needed between the risk and 
benefit of drug treatments during pregnancy. 
4.  General conclusions 
1. The use of teratogenic drugs should be avoided 
during pregnancy in less severe (non life-threatening) 
diseases such as acne and psoriasis. Int. J. Med. Sci. 2005 2  104
2 .  I t  i s  n e c e s s a r y  t o  s e lect non-teratogenic drugs 
instead of teratogenic drugs during pregnancy if possible 
and not harmful for pregnant women. The best example 
for this strategy is to replace coumarin derivative with 
heparin in early pregnancy. 
3. The necessary use of teratogenic drugs may have 
t o  b e  c o n t i n u e d  i n  s e v e r e  m a t e r n a l  d i s e a s e s  s u c h  a s  
epilepsy and cancer if the discontinuation of treatment 
causes worsening of the disease and pregnant women 
agree with it. 
4. Teratogenic drugs cannot cause CAs if the 
exposure is in the first month of gestation and in general 
after the third month of pregnancy. However, the 
fetotoxic effect of some drugs should be considered in the 
second part of pregnancy. 
5. Recent effective ultrasound scanning can detect 
major fetal defects about the 18th-20th week of gestation 
with a high degree of efficacy. Thus we have a chance to 
evaluate the risk after the inadvertent or necessary use of 
teratogenic drugs during pregnancy. If serious fetal 
defects are detected, the couple can then be given 
information to help them decide whether to terminate 
their pregnancy or not. 
6. The use of non-teratogenic drugs may prevent the 
teratogenic effect of maternal diseases such as diabetes 
mellitus, influenza, and other acute infectious diseases 
with high fever and this preventable part of CAs exceeds 
the proportion of CAs caused by teratogenic drugs. 
7. The periconceptional folic acid-containing 
multivitamin supplementation can prevent the major 
proportion of neural-tube defects and a considerable 
portion of cardiovascular, urinary tract CAs and limb 
deficiencies. According to the estimation of the WHO 
expert committee about one-third of major CAs are 
preventable by this new primary preventive method. Folic 
acid alone will also significantly reduce the first 
occurrence and recurrence of neural-tube defects. [52] 
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Tables 
Table 1. Drugs with high and moderate teratogenic risk, their FDA categories and cardinal congenital abnormalities (CAs) and 
the number of their use in the mothers of cases with CA and controls without CAs in the HCCSCA, 1980-2002 
Chemical substance 
(generic name) 
Trade names     FDA risk 
categories  
(%) 
CAs Cases 
(N=29,922) 
Controls 
(N=52,299) 
High risk (more than 25%)           
Thalidomide  Contergan    *  75  Phocomelia,  
CAs of external ear,  
Facial hemangioma 
0 0 
Androgenic hormones       40  Masculinized exter-nal genitalia in girls     
   Danazol  Danoval    X      0  0 
   Methyltestorenone  Ambosex    X      2  0 
   Nandrolone  Nerobolil    X      6  10 
Moderate risk (10-25%)           
Isotretinoin  Accutane    X  25  Microtia  1  1 
 Roaccutan      Cardiac  CAs    
Etretinate  Tigason    X  25  Small ear  0  0 
  Neotigason      Adactyly Cardiac CAs     
Coumarin derivative Warfarin,   
Dicumarol,   
Syncumar 
  D  25  Nasal hypoplasia-depressed nasal 
bridge 
6 8 
Oxytetracycline  Tetramycin,       
Tetran,  
Chlomocycline 
D  20  Staining of deci-duous teeth  206  199 
D-penicillamine Duprenil,   
Byanodine 
  D  15  Cutis laxa  2  3 
Diethylstilbestrol Stilbestrol,   
Syntestrin 
  X  15  Clitoromegaly, Hypotrophic testis  11  8 
Total   No.          234  229 
%        0.8  0.4 
*not approved in USA, therefore thalidomide was not classified 
Table 2. Drugs with low (less than 10%) and very low (less than 3 %) teratogenic risk used in Hungary and the number of cases 
and controls in the HCSCA,1980-2002 
Chemical substances (generic name)  Trade names  FDA category  Cases (N=29922)  Controls 
(N=52599) 
Antineoplastic drugs 
Azathioprine    Imuran    D    2    2 
Cyclophosphamide   Cytoxan   D   2   0 
Chlorambucil   Leukeran    D   0   1  
Mannomustine   Degranol   D   0   5  
Melphalan    Alkeran    D   0   1 
Mercaptopurine    Leupurin    D    0    1 
Methotrexate    Methotrexat    D    1    0 
Mitobronitol    Myelobromol    D    6    19 
Ritrosulfane    Lycurim    D    0    2  
Vincristine    Vincristin    D    2    0 
Subtotal          13    31 Int. J. Med. Sci. 2005 2  106
Anticonvulsant drugs 
Clonazepam    Antelepsin    C    6    5 
    Clonazepamum       
    Rivotril       
Carbamazepine    Azepal    B    47    41 
    Neurotop       
    Stazepine       
    Tegretol       
    Temporal       
    Timonl       
Ethosuximide    Suxilep    C    4    3 
Lamotrigine    Lamictal    C    10    1 
Mephenytoin    Sacerno    C    8    5 
Morsuximide    Perlepsin    *    4    4 
Oxcarbazepine      Trileptal     D  1     0 
Phenacemide    Neophedan    *    3    2 
Phenytoin    Epanutin    D    35    39 
    Diphedan       
Primidone    Mysoline    D    25    13 
    Sertan       
Sultiame    Ospolot    D    12    2 
Trimethadione    Ptimal    D    4    1 
Valproic acid    Convulex    D    41    15 
    Depakine       
    Everiden       
    Orfiril       
Subtotal          200    131 
Others 
Ergotamine    Ergam    D    37    64 
    Kefalgin       
    Neo-Gynofort       
    Secadol       
        
Oestrogens very high dose    Akrofollin    D    20 (40)    8 (43) 
    Hogival          
    Limovan       
    Limovanil       
    Ovestin       
    Strytanon       
Methimazole (thiamazole)    Metothyrin    D    10    1 
Misoprostol    Cytotex    X    0    1 
Lithium    Litium karbonat    D    10    16 
Quinine    Chinidinum    D    40    85 
    Chinacisal       
    Diapulmon       
Retinol very large dose   Vitamin A    A (X)    0 (39)    4 (95) 
Total No.          340    341  
 %          1.1   0.6  
*not approved in USA, therefore was not classified 
Table 3. Comparative analysis of CAs induced by human teratogenic drugs and maternal hyperthermia due to influenza and 
acute infectious diseases of respiratory system  
Human teratogenic drugs    Maternal hyperthernia due to influenza and 
acute infectious respiratory diseases 
Cases Controls    Cases Controls 
   Entire  pregnancy    
1.9% 1.1%    14.5%  13.4% 
OR with 95% CI    OR with 95% CI 
1.79 (1.59 – 2.01)  Second and third months  1.09 (1.04 – 1.15) 
1.4% 0.8%    4.5% 3.7% 
OR with 95% CI    OR with 95% CI 
1.74 (1.52 – 2.00)  1.25 (1.15 – 1.36) 
6.0 (4.2 – 8.0) 
No. of CAs per 1000 informative offspring 
due to teratogenic factors under study  8.7 (5.3 – 12.5) 
 